RxDoctor Payments Data

Danielle Turdo

Family · Philadelphia, PANPI 1598207466

Payments from drug & device makers

$4,759in general payments, 2019–2025

Across 60 payments — averaging $79.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$2K
  • Johnson & Johnson$2K
  • AstraZeneca$217
  • Incyte Corporation$180
  • Sanofi$164
  • Amgen$149
  • plus $313 from 10 others

What the payments were for

  • Consulting fees$1,53532%
  • Speaking & faculty fees$1,29027%
  • Travel & lodging$421%
  • Food & beverage$1,89240%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,759 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$40,535
Medicare patients
79
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide70$1,386,153
OnuregAzacitidine18$406,355
VenclextaVenetoclax28$382,311
Lenalidomide24$376,825
RezurockBelumosudil Mesylate12$339,981
PomalystPomalidomide15$333,787
TasignaNilotinib Hcl17$324,763
JakafiRuxolitinib Phosphate11$186,890
Imatinib Mesylate15$11,387
EliquisApixaban15$9,384
Atovaquone16$3,331
Acyclovir85$1,338
Fluconazole15$581
ValacyclovirValacyclovir Hcl16$412
Lidocaine-PrilocaineLidocaine/Prilocaine19$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$25$382,31128 claims
Sanofi-aventis U.S. LLCRezurock$1,875$339,98112 claims
NovartisTasigna$75$324,76317 claims
Incyte CorporationJakafi$180$186,89011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →